This is a list of investigational restless legs syndrome drugs, or drugs that are currently under development for clinical use for the treatment of restless legs syndrome (RLS) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action [Reference]". This list was last comprehensively updated in September 2025. It is likely to become outdated with time.
Under development
Phase 3 Ferric carboxymaltose (Ferinject; Injectafer; Iron-dextri-maltose; Iroprem; Renegy; VIT-45; Z-213) – iron replacement [1]
Phase 2 BP-14979 (BP-1.4979) – dopamine D3 receptor partial agonist [2] Ropinirole transdermal (Haruropi Tape; HP-3000) – dopamine D2-like receptor agonist [3]
Preclinical ATH-399A (DWP-307399; HL-192) – nuclear receptor subfamily 4 group A member 2 (NR4A2) agonist [4]
Not under development
Suspended Aplindore (DAB-452; Palindore; SLS-006; WAY-DAB-452) – dopamine D2-like receptor agonist [5]
No development reported NLS-2 (NLS2) – iron replacement [6] Research programme: cannabinoid-based therapeutics - Axim Biotechnologies (Cannabidiol/Gabapentin; Cannbleph) – various actions [7]
Discontinued Entacapone (Comtan; Comtess; OR-611) – catechol O-methyltransferase (COMT) inhibitor [8] IPX-159 – undefined mechanism of action [9] Istradefylline (KW-6002; Nourianz; Nouriast) – adenosine A2A receptor antagonist [10] Pregabalin (CI-1008; isobutylgaba; Lyrica; PD-144723) – gabapentinoid (α2δ subunit-containing voltage-gated calcium channel ligand) [11] Radafaxine (GW-353162; (2S,3S)-hydroxybupropion) – norepinephrine–dopamine reuptake inhibitor (NDRI) [12] Research programme: dopamine receptor agonists - DarPharma (DAR-0300) – dopamine receptor agonist [13] [14] Safinamide (EMD-1195686; Equfina; FCE-26743; ME-2125; NW-1015; Onstryv; PNU-151774; Xadago; ZP-034) – monoamine oxidase MAO-B inhibitor and other actions [15]
Clinically used drugs
Approved drugs Gabapentin enacarbil (ASP-8825; GSK-1838262; Horizant; Regnite; Solzira; XP-13512) – gabapentinoid (α2δ subunit-containing voltage-gated calcium channel ligand) [16] Oxycodone/naloxone (naloxone/oxycodone; Targin; Targinact; Targiniq) – combination of oxycodone (μ-opioid receptor agonist) and naloxone (orally inactive opioid receptor antagonist) (only in severe and treatment-refractory cases) [17] Pramipexole (BI-Sifrol; Daquiran; Mirapex; Mirapexin; Pexola; Sifrol; SND-919) – dopamine D2-like receptor agonist [18] Ropinirole (Adartrel; Repreve; Requip; Ropinirole IR) – dopamine D2-like receptor agonist [19] Rotigotine transdermal (Leganto; N-0437; N-0923; Neupro; Nubrenza; SPM-962) – dopamine D2-like receptor agonist [20]
Off-label drugs Benzodiazepines (GABAA receptor positive allosteric modulators) (e.g., clonazepam) Cannabinoids (cannabinoid receptor modulators) (e.g., cannabis, tetrahydrocannabinol (THC)) Dopamine precursors (indirect dopamine receptor agonists) (e.g., carbidopa/levodopa) Dopamine D2-like receptor agonists (e.g., cabergoline, pergolide) Gabapentinoids (α2δ subunit-containing voltage-gated calcium channel ligands) (e.g., gabapentin, pregabalin) Iron supplements (e.g., ferrous sulfate) Opioids (μ-opioid receptor agonists) (e.g., tramadol, codeine, morphine, oxycodone, hydrocodone, methadone, buprenorphine) (only in severe and treatment-refractory cases) Others (e.g., amantadine, baclofen, bupropion, carbamazepine, clonidine, corticosteroids, dipyridamole, ketamine, lamotrigine, levetiracetam, orphenadrine, oxcarbazepine, perampanel, physostigmine, rasagiline, rifaximin, selegiline, topiramate, valproic acid)
See also List of investigational drugs List of investigational Parkinson's disease drugs
References
External links AdisInsight - Springer
